SUBSCRIBE
SUBSCRIBE
News   Drug Development

Biogen Idec, Inc. (Massachusetts) (JOBS), Elan Corporation PLC (JOBS) Shares Plummet on New Tysabri Review

October 23, 2009 | 
1 min read
Bookmark and Share

Reuters -- European regulators said they have begun a review of the multiple sclerosis drug Tysabri following reports of 23 cases of a potentially deadly brain infection.
Clinical research Postmarket research
Biogen
MORE ON THIS TOPIC
Composite collage picture image of man slide down arrow recession statistics data weird freak bizarre unusual fantasy billboard comics.
MASH
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Profile view, and Mental Illness
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Artwork magazine collage picture of serious confident lady looking big enlargement glass isolated drawing background.
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
 · 
3 min read
 · 
Tristan Manalac
Illustration showing scientist climbing up DNA spiral staircase
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
June 24, 2025
 · 
3 min read
 · 
Tristan Manalac